| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.125 | 39.467 | 50.320 | 42.055 | 39.933 | 38.230 | 59.200 | 53.981 | 57.256 | 59.218 |
| Total Income - EUR | 1.125 | 39.467 | 50.320 | 42.055 | 39.933 | 38.333 | 59.200 | 53.981 | 57.256 | 60.039 |
| Total Expenses - EUR | 0 | 2.285 | 1.352 | 752 | 734 | 1.053 | 483 | 1.296 | 8.887 | 11.021 |
| Gross Profit/Loss - EUR | 1.125 | 37.182 | 48.968 | 41.303 | 39.199 | 37.280 | 58.717 | 52.685 | 48.369 | 49.018 |
| Net Profit/Loss - EUR | 1.091 | 35.998 | 47.459 | 40.324 | 38.001 | 36.213 | 57.083 | 51.603 | 47.897 | 47.307 |
| Employees | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Norge Rx Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 282 | 0 | 0 | 0 | 450 | 161 | 0 | 0 | 0 | 789 |
| Current Assets | 1.180 | 37.448 | 50.485 | 43.329 | 42.125 | 37.022 | 58.139 | 52.777 | 50.563 | 82.866 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.125 | 1.323 | 266 | 588 | 1.583 | 1.819 | 3.340 | 38.300 | 1.563 | 35.427 |
| Cash | 55 | 36.125 | 50.219 | 42.741 | 40.542 | 35.202 | 54.799 | 14.477 | 9.578 | 7.233 |
| Shareholders Funds | 1.136 | 36.043 | 47.647 | 40.680 | 38.487 | 36.758 | 57.649 | 52.248 | 48.637 | 47.949 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 326 | 1.405 | 2.838 | 2.649 | 4.088 | 425 | 490 | 529 | 1.926 | 35.706 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Norge Rx Srl